Denosumab Market Report 2026

The denosumab market size has grown rapidly in recent years. It will grow from $3.67 billion in 2025 to $4.06 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to high prevalence of osteoporosis and bone-related disorders, growing geriatric population, early approvals of denosumab therapies, increasing hospital and specialty clinic capacities, rising awareness of fracture risk among patients.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $6.06 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to advancements in precision medicine and biologics, expansion of homecare and ambulatory services, increased investment in bone health research, introduction of next-generation denosumab formulations, rising demand in emerging markets. Major trends in the forecast period include increased adoption of monoclonal antibodies, expansion of osteoporosis screening programs, personalized treatment approaches for bone metastases, growth in home-based injection therapies, rising awareness of bone health in aging population.

The rising prevalence of osteoporosis is expected to drive the growth of the denosumab market in the coming years. Osteoporosis is a medical condition in which bones become weak, leading to reduced bone density and an increased risk of fractures. Denosumab is used to treat osteoporosis by inhibiting bone resorption through targeting the RANK ligand. For instance, in September 2023, the National Center for Biotechnology Information, a US-based government agency, reported that data from the Canadian Longitudinal Study on Aging showed a prevalence of physician-diagnosed osteoporosis of 12.7% and DXA-confirmed osteoporosis of 5.9% in females among community-dwelling older adults. Additionally, Buttros and colleagues conducted a cross-sectional study revealing a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. Therefore, the increasing prevalence of osteoporosis is fueling the growth of the denosumab market.

The growth of the healthcare industry is expected to further drive the expansion of the denosumab market. The healthcare industry encompasses the provision of medical services, the development of treatments, and the supply of products and technologies to maintain and improve human health. This sector is expanding due to rising demand for medical services driven by aging and growing global populations. Denosumab supports the healthcare industry by offering an effective therapy for osteoporosis and cancer-related bone loss, improving patient outcomes. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the number of hospitals in the US increased to 6,129 in 2023 from 6,093 in 2022. Therefore, the expansion of the healthcare industry is propelling growth in the denosumab market.

Major companies in the denosumab market are focusing on expanding global clinical trials and accelerating regulatory approvals to strengthen their competitive position and widen treatment access. Clinical trials are human-based studies that assess the effectiveness and safety of new drugs or therapies. For instance, in May 2023, Boan Biotech, a China-based biopharmaceutical company, initiated an international multicenter Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, enrolling the first patients in Europe, the U.S., and Japan. These efforts follow its 2022 NMPA approval for Boyoubei in postmenopausal women at high fracture risk. By advancing global clinical development and securing regulatory progress, companies reinforce their competitiveness in the denosumab market.

Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc.

North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the denosumab market by increasing the cost of importing raw materials, biologics manufacturing equipment, and specialty drug components. This has affected production timelines and pricing, particularly for segments like 120 mg dosage forms and specialty clinics in regions such as Asia-Pacific and Europe. While costs have risen, some manufacturers are leveraging tariffs as an opportunity to localize production and optimize supply chains, which may improve resilience and innovation in biologics manufacturing.

The denosumab market research report is one of a series of new reports that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Denosumab is a monoclonal antibody used to treat bone-related conditions, particularly osteoporosis and bone metastases. It works by inhibiting the formation of osteoclasts, reducing bone resorption, increasing bone mineral density, and lowering the risk of fractures.

The main types of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medication used to treat osteoporosis in postmenopausal women who are at high risk of fractures or cannot take other osteoporosis treatments. These drugs are available in 60 mg and 120 mg doses and are used by end users such as hospitals, home care providers, specialty clinics, and ambulatory surgical centers.

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.